Join Growin Stock Community!

Lisata therapeutics, inc.LSTA.US Overview

US StockHealthcare
(No presentation for LSTA)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

LSTA AI Insights

LSTA Overall Performance

LSTA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

LSTA Recent Performance

6.10%

Lisata therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

LSTA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

LSTA Key Information

LSTA Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

LSTA Profile

Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Price of LSTA

LSTA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

LSTA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.07
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
33.80
PB Ratio
2.24
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-1704.86%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.07
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
33.80
PB Ratio
2.24
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-1704.86%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is LSTA's latest earnings report released?

    The most recent financial report for Lisata therapeutics, inc. (LSTA) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating LSTA's short-term business performance and financial health. For the latest updates on LSTA's earnings releases, visit this page regularly.

  • How much cash does LSTA have?

    At the end of the period, Lisata therapeutics, inc. (LSTA) held Total Cash and Cash Equivalents of 19M, accounting for 0.87 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is LSTA's EPS continuing to grow?

    According to the past four quarterly reports, Lisata therapeutics, inc. (LSTA)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.49. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of LSTA?

    Lisata therapeutics, inc. (LSTA)'s Free Cash Flow (FCF) for the period is -3.34M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 32.72% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of LSTA?

    The latest valuation data shows Lisata therapeutics, inc. (LSTA) has a Price-To-Earnings (PE) ratio of -1.14 and a Price/Earnings-To-Growth (PEG) ratio of 0.15. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.